spacer
home > pmps > winter 2017 > made in europe
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Made in Europe

When looking back at the news concerning active pharmaceutical ingredient (API) production and outsourcing published in the past seven years, it seems almost all market analysts were certain about one thing: a massive outflow of API activity to China and India. Some articles forecast an almost certain doom for Western manufacturers. In addition, second wave emerging markets like Brazil and Russia have also been mentioned as future additions to the API family, with the potential of taking over some of the established European production. On the other hand, a few reports focused on companies returning to Europe due to allegedly deteriorating quality and reliability of Indian and Chinese organisations. The market has been in flux, but it looks as if most members of that huge network have found a way to not only survive, but to grow or even thrive.

China and India have become dominant players in the global API market and their position is expected to grow. Businesses in these two countries are well aware of their strength and endeavour to take full advantage of it when it comes to their own markets as well as those overseas. The mixture of low wages for basic workers, sixday working weeks and many Americanand European-educated analysts with foreign experience are just some of the reasons as to why India has been playing such an important role in the business. For a lot of European companies, closing new deals with such competition in generic APIs is almost impossible.

Barter for a Deal

In many negotiations concerning API manufacturing, what the producers have to face on a daily basis is an arbitration centring on how close they can get to the price that has been offered to the customer by an Eastern firm. In the past, for APIs which were not produced by big pharmaceutical companies themselves, it was much easier to convince clients that those originating from Europe were meeting the highest possible standards, manufactured close to them and would be delivered in time. Those outsourcing often found this comforting as it usually meant that the facility was therefore in a convenient inspection range.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jiri Raska is the Commercial Director of Farmak, a traditional European generic API manufacturer in the Czech Republic. He has over 12 years of experience in the pharma industry and has been responsible for quality control, project management and business development. Jiri’s current duties cover sales and the marketing of niche APIs to several countries around the world.
spacer
Jiri Raska
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Dempsey Demystifies Regulatory Cycle at DIA Europe

March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director, Sheena Dempsey, will present “Demystifying the Multilingual Complexities in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM (CET), in Basel, Switzerland.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement